Central Florida Pulmonary Group,PA
Orlando, Florida 32825
3 studies enrolling now · 46 studies all time
What they study most
Alpha 1-Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency, Asthma, Bronchiectasis, COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Heart Failure With Preserved Ejection Fraction, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Lung Cancer
Studies at this site
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
- Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS — Recruiting now
- OLE Therapy With BE Patients in Home Care Study — Recruiting now
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease — Enrolling by invitation
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy — Running, not enrolling
- Screening for High Frequency Malignant Disease — Running, not enrolling
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis — Completed
- A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis — Completed
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Running, not enrolling
- A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis — Stopped early
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy — Completed
- A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype — Stopped early
- To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF — Completed
- Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis — Completed
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) — Completed
- A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation — Completed
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis — Stopped early
- A Phase 1, First-in-human Study of VX-668 — Completed
- A Phase 1, First-in-human Study of VX-634 — Completed
- Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy — Completed
- JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF — Completed
- Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD — Completed
- Acthar Gel in Participants With Pulmonary Sarcoidosis — Completed
- Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH — Stopped early
- Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis — Completed
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis — Completed
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care — Stopped early
- Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype — Stopped early
- A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis — Completed
- A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis — Completed
- Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
- GB001 in Adult Subjects With Moderate to Severe Asthma — Completed
- Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF) — Completed
- A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) — Completed
- Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction — Stopped early
- A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects — Completed
- Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF — Stopped early
- A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1) — Stopped early
- A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) — Completed
- Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis — Completed
- A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Completed
- Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program — Completed
- A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis — Completed
- Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies — Completed